Morgan Stanley raises Mirum Pharmaceuticals target to $150
Morgan Stanley analyst Michael Ulz maintained an Overweight rating on Mirum Pharmaceuticals and raised the price target to $150 from $140, signaling a strengthened outlook for the company's stock performance.
*this image is generated using AI for illustrative purposes only.
Morgan Stanley analyst Michael Ulz has maintained an Overweight rating on Mirum Pharmaceuticals (NASDAQ: MIRM) while raising the price target to $150 from the previous $140. The adjustment signals a strengthened outlook for the pharmaceutical company's stock performance.
The revised price target of $150 represents an increase from the prior estimate of $140. This change underscores the analyst's positive stance on Mirum Pharmaceuticals' future growth trajectory.
Rating and Target Details
The following table outlines the updated ratings and price targets for Mirum Pharmaceuticals:
| Metric | Value |
|---|---|
| Rating | Overweight |
| Previous Price Target | $140 |
| New Price Target | $150 |
The Overweight rating suggests that the stock is expected to outperform the broader market or its sector peers over the specified period. The increase in the price target indicates a revised valuation based on the company's current fundamentals and market conditions.
What specific clinical or commercial developments drove Morgan Stanley to increase the price target by $10?
How might this rating upgrade influence investor sentiment and trading volume for Mirum Pharmaceuticals in the short term?
What are the potential risks or challenges that could prevent Mirum from reaching the new $150 price target?
16
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
